Detail page

Knowledge Web

Person

Andreas Reiter (1964-)

Arzt

Name	Andreas Reiter
Time	1964- (Date of birth and death)
Place	Deutschland
Academic degree	apl. Prof. Dr. med.
Profession	Arzt (characteristic profession)
Variant	Andreas Johannes Reiter Andreas J. Reiter A. Reiter
Further information	Geschäftsführender Oberarzt in der III. Medizinischen Klinik der Medizinischen Fakultät Mannheim der Universität Heidelberg und Professor für Innere Medizin
Record type	Person
GND-Identifier	172629551
Record ID	172629551
Involved in show all Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5 Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries Myeloische/lymphatische Neoplasien mit Eosinophilie und Tyrosinkinase-Fusionsgenen Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Transcriptomic profiling does not refine mastocytosis diagnosis Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies Prognostische Biomarker und neue Therapieoptionen bei seltenen myeloischen Neoplasien An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis Fortgeschrittene systemische Mastozytose (advSM) - selten oder doch häufiger als man denkt? : was ist bei der Diagnose und Therapie zu beachten? Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis MARS: mutation-adjusted risk score for advanced systemic mastocytosis Prognostischer Effekt zusätzlicher somatischer Mutationen bei KIT D816V positiver systemischer Mastozytose Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia Midostaurin : Multi-Target-Kinase-Hemmer Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL) How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Aktuelles zur systemischen Mastozytose ICON: Eosinophil Disorders Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders Leukocytoclastic Vasculitis and Acute Renal Failure after Influenza Vaccination in an Elderly Patient with Myelodysplastic Syndrome Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection—case report and review of the literature Chronische myeloproliferative Erkrankungen : Diagnostik und Therapie Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie Untersuchungen zum Einfluss von Probenecid auf die Pharmakokinetik von Ciprofloxacin, einem Gyrase-Hemmer

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Andreas Reiter (1964-)

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5

Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries

Myeloische/lymphatische Neoplasien mit Eosinophilie und Tyrosinkinase-Fusionsgenen

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Transcriptomic profiling does not refine mastocytosis diagnosis

Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

Prognostische Biomarker und neue Therapieoptionen bei seltenen myeloischen Neoplasien

An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis

Fortgeschrittene systemische Mastozytose (advSM) - selten oder doch häufiger als man denkt? : was ist bei der Diagnose und Therapie zu beachten?

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

Prognostischer Effekt zusätzlicher somatischer Mutationen bei KIT D816V positiver systemischer Mastozytose

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia

Midostaurin : Multi-Target-Kinase-Hemmer

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL)

How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera

Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Aktuelles zur systemischen Mastozytose

ICON: Eosinophil Disorders

Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders

Leukocytoclastic Vasculitis and Acute Renal Failure after Influenza Vaccination in an Elderly Patient with Myelodysplastic Syndrome

Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection—case report and review of the literature

Chronische myeloproliferative Erkrankungen : Diagnostik und Therapie

Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie

Untersuchungen zum Einfluss von Probenecid auf die Pharmakokinetik von Ciprofloxacin, einem Gyrase-Hemmer